Comparison of Long-Term Clinical Outcomes of CHOP Chemotherapy between Japanese Patients with Nodal Peripheral T-Cell Lymphomas and Those with Diffuse Large B-Cell Lymphoma in the Study Group of the Tohoku Hematology Forum

Tomoaki Akagi; Naoto Takahashi; Kouhei Yamaguchi; Kenichi Ishizawa; Kazunori Murai; Katsushi Tajima; Kazuhiko Ikeda; Yoshihiro Kameoka; Junnichi Kameoka; Shigeki Ito; Yuichi Kato; Hideyoshi Noji; Tsutomu Shichishima; Jugoh Itoh; Ryo Ichinohasama; Hideo Harigae; Yoji Ishida; Kenichi Sawada

doi:10.3960/jslrt.51.29

Original Article

Comparison of Long-Term Clinical Outcomes of CHOP Chemotherapy between Japanese Patients with Nodal Peripheral T-Cell Lymphomas and Those with Diffuse Large B-Cell Lymphoma in the Study Group of the Tohoku Hematology Forum

Tomoaki Akagi, Naoto Takahashi, Kouhei Yamaguchi, Kenichi Ishizawa, Kazunori Murai, Katsushi Tajima, Kazuhiko Ikeda, Yoshihiro Kameoka, Junnichi Kameoka, Shigeki Ito, Yuichi Kato, Hideyoshi Noji, Tsutomu Shichishima, Jugoh Itoh, Ryo Ichinohasama, Hideo Harigae, Yoji Ishida, Kenichi Sawada

Author information

Tomoaki Akagi
Department of Hematology, Aomori Prefectural Hospital
Naoto Takahashi
Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine
Kouhei Yamaguchi
Department of Hematology, Aomori Prefectural Hospital
Kenichi Ishizawa
Department of Rheumatology and Hematology, Tohoku University School of Medicine
Kazunori Murai
Department of Hematology/Oncology, Internal Medicine, Iwate Medical University
Katsushi Tajima
Department of Neurology, Hematology, Metabolism, Endocrinology, and Diabetology, Faculty of Medicine, Yamagata University
Kazuhiko Ikeda
Department of Cardiology and Hematology, Fukushima Medical University
Yoshihiro Kameoka
Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine
Junnichi Kameoka
Department of Rheumatology and Hematology, Tohoku University School of Medicine
Shigeki Ito
Department of Hematology/Oncology, Internal Medicine, Iwate Medical University
Yuichi Kato
Department of Neurology, Hematology, Metabolism, Endocrinology, and Diabetology, Faculty of Medicine, Yamagata University
Hideyoshi Noji
Department of Cardiology and Hematology, Fukushima Medical University
Tsutomu Shichishima
Department of Cardiology and Hematology, Fukushima Medical University
Jugoh Itoh
Department of Medical Oncology, Hirosaki University Graduate School of Medicine
Ryo Ichinohasama
Department of Hematopathology, Tohoku University School of Medicine
Hideo Harigae
Department of Rheumatology and Hematology, Tohoku University School of Medicine
Yoji Ishida
Department of Hematology/Oncology, Internal Medicine, Iwate Medical University
Kenichi Sawada
Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine

Keywords: peripheral T-cell lymphomas, diffuse large B-cell lymphoma, survival, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)

JOURNAL FREE ACCESS

2011 Volume 51 Issue 1 Pages 29-35

DOI https://doi.org/10.3960/jslrt.51.29

Details

Abstract

To clarify the clinical outcome of peripheral T-cell lymphomas (PTCLs), we conducted a retrospective review comparing the outcomes of patients with PTCL (nodal peripheral T-cell lymphoma, unspecified, n=34 ; angioimmunoblastic T-cell lymphoma, n=12) to those with diffuse large B-cell lymphoma (DLBCL, n=48). All patients received CHOP-based chemotherapy without rituximab. PTCL patients presented at a more advanced clinical stage (91% vs. 65%, P<0.002) with a poorer performance status (26% vs. 17%, P<0.002) than DLBCL patients. The complete response rate among PTCL patients was significantly lower than among DLBCL patients (39% vs. 67%, P<0.008), as was the 3-year overall survival rate (26% vs. 50%, P=0.005), and Cox multivariate analysis revealed immunophenotype, performance status, and extranodal site involved to be significantly associated with shorter overall survival (P=0.045, P=0.007, and P=0.034, respectively). Our findings suggest that PTCL patients tend to have a poor prognosis associated with several initial risk factors. Moreover, the T-cell phenotype itself appears to have a significant impact on overall survival. Thus, standard CHOP chemotherapy may be inadequate for PTCLs, especially in patients with high-risk factors. The development of newly stratified therapies for the treatment of PTCLs would be highly desirable. [J Clin Exp Hematopathol 51(1) : 29-35, 2011]

Corresponding author

Register with J-STAGE for free!